Complete Genomics DNBseq T1+

The National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health, is seeking to procure a Complete Genomics DNBseq T1+ sequencer through a sole source acquisition. This genomic sequencing instrument will support the NIEHS Epigenomics core facility to increase sequencing capacity and enhance research capabilities. The DNBseq T1+ is characterized as a highly efficient mid-throughput sequencing platform featuring Q40 accuracy and flexible sequencing options, with particular capability for supporting Stereo-seq spatial transcriptomics methodology. Interested parties must submit electronic responses to the Contracting Officer by September 4, 2025 at 9:00 AM Eastern time. Response requirements include technical and cost proposals, period of performance details, Unique Entity ID, Taxpayer Identification Number, and business size certification. All potential offerors must maintain active registration in the System for Award Management (SAM).

This procurement does not utilize any set-aside designation and is specifically targeted to Complete Genomics LLC located in San Jose, California as the sole source vendor. The contract value falls under the simplified acquisition threshold of $250,000, indicating a relatively modest procurement size for the federal government. The DNBseq T1+ sequencer is capable of delivering between 25 gigabytes to 1.2 terabytes of sequencing data in less than 24 hours, demonstrating its substantial throughput capabilities. The procurement is classified under NAICS code 334516 for Analytical Laboratory Instrument Manufacturing and PSC category 6515 for Medical and Surgical Instruments, Equipment, and Supplies. The solicitation number is 75N94025Q00200, and the acquisition is designed to be completed efficiently given the specialized nature of the required genomic sequencing technology.